Is There Any Association between Glutathione S‑transferases M1 and Glutathione S‑transferases T1 Gene Polymorphisms and Endometrial Cancer Risk? A Meta‑analysis

Abstract

Epidemiological evidence on the association between genetic polymorphisms in glutathione S‑transferases M1 (GSTM1) and T1 (GSTT1) genes and risk of endometrial cancer (EC) has been inconsistent. In this meta‑analysis, we seek to investigate the relationship between GSTM1
and GSTT1 polymorphisms and the risk of EC. We searched Medline, PubMed, Web of Science, Embase, Chinese National Knowledge Infrastructure database, and Chinese Biomedical Literature database to identify eligible studies. The pooled odds ratios (ORs) with 95% confdence
intervals (CIs) for the association were determined using a fxed‑ or random‑effect model. Tests for heterogeneity of the results and sensitivity analyses were performed. A total of six case–control studies were included in the fnal meta‑analysis of GSTM1 (1293 cases and 2211 controls) and
GSTT1 (1286 cases and 2200 controls) genotypes. Overall, GSTM1 null genotype was not signifcantly associated with an increased risk of EC (OR = 1.00, 95% CI = 0.76–1.30, P = 0.982). Similarly, for GSTT1 deletion genotype, we observed no association under the investigated model
in the overall analysis (OR = 0.91, 95% CI = 0.64–1.30, P = 0.619). Subgroup analysis also showed no signifcant association between the GSTM1 null genotype and EC risk in hospital‑based design (OR = 1.26, 95% CI = 0.93–1.71, P = 0.131) and no relationship between GSTT1 null
genotype with EC risk in population‑based design (OR = 1.18, 95% CI = 0.79–1.76, P = 0.407). However, GSTM1 null genotype contributed to an increased EC risk in population‑based design (OR = 0.76, 95% CI = 0.60–0.97, P = 0.027), while null GSTT1 in hospital‑based studies
(OR = 0.70, 95% CI = 0.52–0.93, P = 0.015). The present meta‑analysis suggested that GSTs genetic polymorphisms may not be involved in the etiology of EC. Large epidemiological studies with the combination of GSTM1 null, GSTT1 null, and design‑specifc with the development of EC
are needed to prove our fndings.

Keywords: Endometrial cancer, glutathione S‑transferases M1, glutathione S‑transferases T1, meta‑analysis, susceptibility